

Biglaw Tries to Persuade Judge Not to Send One of Their Own to Prison

News

Some former colleagues of the lawyer who was convicted of conspiracy to commit securities fraud and conspiracy to commit wire fraud in connection with the “Pharma Bro” case are asking the judge in his case for leniency.

Dubious Corporate Practices Get a Rubber Stamp From Big Investors

News

Institutional asset managers carry enormous clout across corporate America. So it’s unfortunate that so many of these managers choose to support the status quo for boards, even when investors are ill served, points out *The New York Times*.

Platinum

Hedge

Fund

Executives Charged With \$1 Billion Fraud

News

The New York Times reports that federal agents arrested Mark Nordlicht, a founder and the chief investment officer of Platinum, and six others on charges related to an alleged \$1 billion fraud.

How to Roll Out the Best-Interest Contract Exemption

Insight

Advisers should learn how to incorporate the best-interest contract exemption into their practices if they help clients plan for retirement, reports Kenneth Corbin for FinancialPlanning.

Burford Capital PLC Burford Capital Appoints Craig Arnott Managing Director

News

Arnott will be based in London and will have as his primary focus Burford's litigation financing activities in the UK,

continental Europe and the Asia – Pacific region.

Bank Regulators Revive Restrictions on Incentive-Based Compensation

Article

The new rules seek to establish general requirements applicable to the incentive-based compensation arrangements of covered persons working in covered institutions.

Reverse Break-Up Fees and Specific Performance: A Survey of Remedies

White Paper

Thomson Reuters is offering a complimentary copy of the 2016 edition of Practical Law's study, Reverse Break-Up Fees and Specific Performance: A Survey of Remedies for Financing and Antitrust Failure.

Latham & Watkins Advises Second Genome in \$42.6 Million Series B Financing

News

Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, has closed an oversubscribed Series B investment round with \$42.6 million in financing.

Global M&A Roundup Shows 'Perfect Storm for Acquisition Finance'

White Paper

Law firm Skadden Arps Slate Meagher holds on to the number one spot for deal value for another year while Latham & Watkins jumps from fourth to second last year.

Bankler Report: Congressional Tax Bill

Analysis

Will you or your law firm practice be affected by this week's

compromise by Congressional leaders regarding taxes and deductions if it becomes law?

Latham & Watkins Advises Gritstone Oncology in Its Formation and Financing

NEWS

Gritstone Oncology, a cancer immunotherapy company developing next-generation, personalized cancer therapeutics, has announced a Series A financing of \$102 million.